GlassScriptPhysician profile
Rishi Sood
NPI 1356575666
$971.69
in general payments reported to CMS, 2019-2025
16 companies · $70.62 in 2025
The $70.62 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $32.09 · 2022: $115 · 2023: $43.88 · 2024: $192 · 2025: $70.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $149.15 | 2019 | |
| Corium, LLC | $117.00 | 2024 | Azstarys |
| Baxter Healthcare | $115.38 | 2022 | |
| Shire North American Group INC | $101.35 | 2019 | |
| Tempus Ai, INC | $75.00 | 2024 | |
| Allergan, INC. | $72.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $66.74 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $64.38 | 2019 | |
| Bausch Health US, LLC | $35.87 | 2019 | |
| Adlon Therapeutics L.P. | $34.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.19 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.18 | 2025 | Uzedy |
| Neos Therapeutics, LP | $22.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.58 | 2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $18.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $18.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.